2017 J.P.Morgan Healthcare Conference: Large Cap Biotechs Compared to 2016

Large Cap Biopharma Stock Performance YoY from J.P.Morgan Conference

The market recovered slightly today from yesterday’s “Trump storm” attacking drug prices. The IBB rose 0.36% and the XBI rose 1.56% . The healthcare sector overall was flat.

Selected stocks that continued their upward trend from earlier this week are: Array Biopharma (ARRY) up 7.3%  -Five year high, bluebird bio (BLUE) up 1.77%, Clovis Oncology (CLVS), Incyte (INCY) up 1.96%, Intercept Pharmaceuticals up 4.2%, Merck (MRK) up 0.94% and Seattle Genetics (SGEN) up 5.4%.

Here is my Large Cap Biopharmaceutical Performance Summary for 2016 at this time last year (1/7/16) at the Conference.

Here is a comparison of these 8 large cap biopharmaceutical companies’ stocks performance YoY 1/7/16 vs 1/12/17. Abbvie (ABBV) was up 7% and compared to the IBB down 7.3%.

Abbvie (ABBV) $57.21 to 61.28Up 7%

Alexion (ALXN) $174.37 to 137.35

Amgen (AMGN) $152.98 to 155.36

Biogen (BIIB) $284.01 to 287.77

Bristol-MyersS (BMY) $65.27 to 56.55

Celgene (CELG)$111.89 to 117.08-  Up 4.5%

Gilead Sciences (GILD) $96.25 to 73.36

Regeneron (REGN) $501.96 to 364.44, down 27.5%

IBB $302 to $280,high of $326 on 1/1/16; low of $244 on 2/11/16

Top gainers YoY are: ABBV, CELG and AMGN.

Top losers YoY are: ALXN, REGN and GILD. 

 

 

, , , , , ,

No comments yet.

Leave a Reply